Immune promoting therapy for the treatment of cytomegalovirus pneumonia after renal transplantation: A perspective randomized control trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-08000282

Enrollment

Unknown

Registered

2008-12-26

Start date

2009-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cytomegalovirus pneumonia after renal transplantation

Interventions

Group A:For patients with mild to moderate pneumonia, immunoglobulin was given 5-10g/day intravenously and for those with severe pneumonia, dose of immunoglobulin was 10-20g/day.

Group B:For patients with mild to moderate pneumonia, Anti-cytomegalovirus immunoglobulin was given 50U/Kg once every two days (4-6 times in total) dripping intravenously and for those with severe pne

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Male and female aged 18 to 70 years old; 2. Patients received Allograft of cadaveric kidney; 3. Cause of the first admission to hospital was cytomegalovirus pneumonia; 4. Signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Allergy or intolerant to agents in integrate medication; 2. Pneumonia was caused by other pathogen.

Design outcomes

Primary

Measure	Time frame
Average hospital days;Recovery rate of cytomegalovirus pneumonia;	—

Secondary

Measure	Time frame
Survival rate of human kidney;Incidence of acute rejection;Serum creatinin;	—

Countries

China

Contacts

Public ContactLizhong Chen

clz@medmail.com.cn+86 0 13902303569

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026